Efficacy and safety of DPP-4 inhibitor in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis

BACKGROUND: DM is a common chronic metabolic disease. COVID-19 is a large-scale infectious disease. Some studies have shown that DM is an independent risk factor that increases COVID-19 mortality or other adverse outcomes. There is currently no specific and effective drug treatment. More and more pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yan, Xie, Hongyan, Gao, Hong, Xie, Chunguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544298/
https://www.ncbi.nlm.nih.gov/pubmed/33031311
http://dx.doi.org/10.1097/MD.0000000000022592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544298/
https://www.ncbi.nlm.nih.gov/pubmed/33031311
http://dx.doi.org/10.1097/MD.0000000000022592

Ejemplares similares